Eicosanoids derived from arachidonic acid and their family prostaglandins and cyclooxygenase in psychiatric disorders

Current Neuropharmacology

Volumn 13, Issue 6, 2015, Pages 776-785

  Yui, Kunio ^a   Imataka, George ^b   Nakamura, Hiroyuki ^c   Ohara, Naoki ^d   Naito, Yukiko ^e  

^a Ashiya University   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d KINJO GAKUIN UNIVERSITY   (Japan)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Alzheimer s disease; Arachidonic acid; Autism spectrum disorder; Cyclooxygenases 1 inhibitors; Cyclooxygenases 2 inhibitors; Depression; Eicosanoids; Schizophrenia

Indexed keywords

ALPHA INTERFERON; ARACHIDONIC ACID; CELECOXIB; ICOSANOID; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA; PROSTAGLANDIN; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; ARTICLE; AUTISM; BIPOLAR DEPRESSION; DOWN REGULATION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; MAJOR DEPRESSION; MENTAL DISEASE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; SCHIZOPHRENIA; UPREGULATION; ANIMAL; MENTAL DISORDERS; METABOLISM;

ANIMALS; ARACHIDONIC ACID; HUMANS; MENTAL DISORDERS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PSYCHOTROPIC DRUGS;

EID: 84959312323     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X13666151102103305     Document Type: Article

References (99)

1. Capra, V., Rovati, G.E., Mangano, P., Buccellati, C., Murphy, R.C., Sala, A. Transcellular biosynthesis of eicosanoid lipid mediators. Biochim. Biophys. Acta., 2014, pii: S1388-1981(14)00174-7. doi: 10.1016/j.bbalip.2014.09.00
2. Harizi, H., Corcuff, J.B., Gualde, N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol. Med., 2008, 14(10), 461-469. doi: 10.1016/j.molmed.2008.08.005.
3. Wymann, M.P., Roger Schneiter, R. Lipid signalling in disease. Nature Reviews Molecular Cell Biology, 2008, 9(2), 162-176. doi: 10.1038/nrm2335.
4. Hallahan, B., Garland, M.R.: Essential fatty acids and mental health. Br. J. Psychiatry., 2005, 186, 275-277. http://dx.doi.org/10.1192/bjp.186.4.275
5. Harizi, H., Corcuff, J.B., Gualde, N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol. Med., 2008, 14(10):461-469. doi: 10.1016/j.molmed.2008.08.005.
6. Khanapure, S.P., Garvey, D.S., Janero, D.R., Letts, L.G. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr. Top. Med. Chem., 2007, 7(3), 311-340. http://dx.doi.org/10.2174/156802607779941314
7. Yin, H., Zhou, Y., Zhu, M., Hou, S., Li, Z., Zhong, H., Lu, J., Meng, T., Wang, J., Xia, L., Xu, Y., Wu Y. Role of mitochondria in programmed cell death mediated by arachidonic acid-derived eicosanoids. Mitochondrion, 2013, 13(3), 209-224. doi: 10.1016/j.mito.2012.10.003.
8. Ong, W.Y., Farooqui, T., Farooqui, A.A. Involvement of cytosolic phospholipase A(2), calcium independent phospholipase A(2) and plasmalogen selective phospholipase A(2) in neurodegenerative and neuropsychiatric conditions. Curr. Med. Chem., 2010, 17(25):2746-2763. http://dx.doi.org/10.2174/092986710791859289
9. Huber, C., Marschallinger, J., Tempfer, H., Furtner, T., Couillard-Despres, S., Bauer, H.C., Rivera, F.J., Aigner, L. Inhibition of leukotriene receptors boosts neural progenitor proliferation. Cell Physiol. Biochem., 2011, 28(5), 793-804. doi: 10.1159/000335793. Epub 2011 Dec 15.
10. Puppolo, M., Varma, D., Jansen, S.A. A review of analytical methods for eicosanoids in brain tissue. J. Chromatog. B Analyt. Technol. Biomed. Life Sci., 2014, 964, 50-64. doi: 10.1016/j.jchromb.2014.03.007.
11. Rao, J.S., Kim, H.W., Harry, G.J., Rapoport, S.I., Reese, E.A. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr. Res., 2013, 147(1), 24-31. doi: 10.1016/j.schres.2013.02.017. Epub 2013 Apr 6.
12. Tamiji, J., Crawford, D.A. The neurobiology of lipid metabolism in autism spectrum disorders. Neurosignals, 2010, 18, 98-112. doi: 10.1159/000323189.
13. Chen, C.Y., Tzeng, N.S., Chen, Y.C. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen. Hosp. Psychiatry, 2010, 32(6), 647. e7-9. doi: 10.1016/j.genhosppsych.2010.07.001.
14. Wei, L.L., Shen, Y.D., Zhang, Y.C., Hu, X.Y., Lu, P.L., Wang, L., Chen, W. Roles of the prostaglandin E2 receptors EP subtypes in Alzheimer's disease. Neurosci. Bull., 2010, 26(1), 77-84. doi: 10.1007/s12264-010-0703-z
15. Piro, J.R., Benjamin, D.I., Duerr, J.M., Pi, Y., Gonzales, C., Wood, K.M., Schwartz, J.W., Nomura, D.K., Samad, T.A. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep., 2012, 1(6), 617-623. doi: 10.1016/j.celrep.2012.05.001. Epub 2012 Jun 21.
16. Mizuno, M., Sotoyama, H., Narita, E., Kawamura, H., Namba, H., Zheng, Y., Eda, T., Nawa H.: A cyclooxygenase-2 inhibitor ameliorates behavioral impairments induced by striatal administration of epidermal growth factor. J. Neurosci., 2007, 27(38), 10116-101127. http://dx.doi.org/10.1523/JNEUROSCI.2368-07.2007
17. Cahill-Smith, S., Li, J.M. Oxidative stress, redox signalling and endothelial dysfunction in ageing-related neurodegenerative diseases: a role of NADPH oxidase 2. Br. J. Clin. Pharmacol., 2014, 78(3), 441-453. http://dx.doi.org/10.1111/bcp.12357
18. James, S.J., Cutler, P., Melnyk, S., Jernigan, S., Janak, L., Gaylor, D.W., Neubrander, J.A.: Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr., 2004, 80(6), 1611-1617.
19. Rose, S., Frye, R.E., Slattery, J., Wynne, R., Tippett, M., Pavliv, O., Melnyk, S., James, S.J.: Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort. PLoS One, 2014, 9(1), e85436. doi: 10.1371/journal.pone.0085436.eCollection2014.
20. Beaulieu, E., Ioffe, J., Watson, S.N., Hermann, P.M., Wildering, W.C. Oxidative-stress induced increase in circulating fatty acids does not contribute to phospholipase A2-dependent appetitive longterm memory failure in the pond snail Lymnaea stagnalis. BMC Neurosci., 2014, 15, 56. doi: 10.1186/1471-2202-15-56.
21. Yagami, T., Yamamoto, Y., Koma, H. The role of secretory phospholipase A_ in the central nervous system and neurological diseases. Mol. Neurobiol., 2014, 49(2), 863-876. doi: 10.1007/s12035-013-8565-9.
22. Komiya, Y., Habas, R. Wnt signal transduction pathways. Organogenesis, 2008, 4(2), 68-75. http://dx.doi.org/10.4161/org.4.2.5851
23. Wong, C.T., Ahmad, E., Li, H., Crawford, D.A. Prostaglandin E2 alters Wnt-dependent migration and proliferation in neuroectodermal stem cells: implications for autism spectrum disorders. Cell Commun. Signal., 2014, 11, 160. doi: 10.1186/1478-811X-12-19.
24. El-Ansary, A., Al-Ayadhi L.: Lipid mediators in plasma of autism spectrum disorders. Lipids Health Dis., 2012, 21, 11: 160. doi: 10.1186/1476-511X-11-160.
25. Ong, W.Y., Farooqui, T., Farooqui, A.A. Involvement of cytosolic phospholipase A(2), calcium independent phospholipase A(2) and plasmalogen selective phospholipase A(2) in neurodegenerative and neuropsychiatric conditions. Curr. Med. Chem., 2010, 17(25), 2746-2763. http://dx.doi.org/10.2174/092986710791859289
26. Su, L.D., Wang, D.J., Yang, D., Shen, Y., Hu, Y.H. Retrograde cPLA2α/arachidonic acid/2-AG signaling is essential for cerebellar depolarization-induced suppression of excitation and long-term potentiation. Cerebellum, 2013, 12(3), 297-299. doi: 10.1007/s12311-012-0444-9.
27. Matsuo, M., Hamasaki, Y., Fujiyama, F., Miyazaki, S. Eicosanoids are produced by microglia, not by astrocytes, in rat glial cell cultures. Brain Res., 1995, 685(1-2), 201-204. http://dx.doi.org/10.1016/0006-8993(95)00490-H
28. Singh, D.P., Chopra, K. Flavocoxid, dual inhibitor of cyclooxygenase-2 and 5-lipoxygenase, exhibits neuroprotection in rat model of ischaemic stroke. Pharmacol. Biochem. Behav., 2014, 120, 33-42. doi: 10.1016/j.pbb.2014.02.006.
29. Badie, B., Schartner, J.M., Hagar, A.R., Prabakaran, S., Peebles, T.R., Bartley, B., Lapsiwala, S., Resnick, D.K., Vorpahl, J. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin. Cancer Res., 2003, 9(2), 872-877.
30. Pistritto, G., Ciabattoni, G., Mancuso, C., Tringali, G., Preziosi, P., Navarra, P. Signaling pathways involved in lipopolysaccharide stimulation of prostaglandin production by rat hypothalamic astroglial cells. J. Endotoxin. Res., 2000, 6(4), 307-311. http://dx.doi.org/10.1177/09680519000060040601
31. Clasadonte, J., Poulain, P., Hanchate, N.K., Corfas, G., Ojeda, S.R., Prevot, V. Prostaglandin E2 release from astrocytes triggers gonadotropin-releasing hormone (GnRH) neuron firing via EP2 receptor activation. Proc. Natl. Acad. Sci. U. S. A., 2011, 108(38), 16104-16109. doi: 10.1073/pnas.1107533108
32. Mohri, I., Taniike, M., Taniguchi, H., Kanekiyo, T., Aritake, K., Inui, T., Fukumoto, N., Eguchi, N., Kushi, A., Sasai, H., Kanaoka, Y., Ozono, K., Narumiya, S., Suzuki, K., Urade, Y. Prostaglandin D2-mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher. J. Neurosci., 2006, 26(16), 4383-4393. http://dx.doi.org/10.1523/JNEUROSCI.4531-05.2006
33. Law, M.H., Cotton, R.G.H., Berger, G.E. The role of phospholipases A2 in schizophrenia Molecular Psychiatry, 2006, 11, 547–556. doi:10.1038/sj.mp.4001819, published online 4 April 2006.
34. Smesny, S., Kunstmann, C., Kunstmann, S., Willhardt, I., Lasch, J., Yotter, R.A., Proffitt, T.M., Kerr, M., Marculev, C., Milleit, B., Milleit, C., Nenadic, I., Amminger, P., McGorry, P.D., Sauer, H., Berger, G.E. Phospholipase A2 activity in first episode schizophrenia: associations with symptom severity and outcome at week 12. World J. Biol. Psychiatry, 2011, 12(8), 598-607. doi: 10.3109/15622975.2010.541283.
35. Riedel, M., Strassnig, M., Schwarz, M.J., Müller N. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs, 2005, 19(10), 805-819. http://dx.doi.org/10.2165/00023210-200519100-00001
36. Müller, N., Schwarz, M.J.: Immune System and Schizophrenia. Curr. Immunol. Rev., 2010, 6(3), 213-220. http://dx.doi.org/10.2174/157339510791823673
37. Gałecki, P., Talarowska, M., Bobińska, K., Szemraj, J. COX-2 gene expression is correlated with cognitive function in recurrent depressive disorder. Psychiatry Res., 2014, 215(2), 488-490. doi: 10.1016/j.psychres.2013.12.017
38. Müller, N., Krause, D., Weidinger, E., Schwarz, M. Immunological treatment options for schizophrenia. Fortschr. Neurol. Psychiatr., 2014, 82(4), 210-219. doi: 10.1055/s-0033-1355776.
39. Schmidt, L., Ceglarek, U., Kortz, L., Hoop, M., Kirkby, K.C., Thiery, J., Himmerich, H. Mechanisms of involvement of eicosanoids and their Precursors in the pathophysiology and treatment of schizophrenia. Med. Chem., 2013, 9(6), 763-773. http://dx.doi.org/10.2174/1573406411309060002
40. Müller, N., Ulmschneider, M., Scheppach, C., Schwarz, M.J., Ackenheil, M., Möller, H.J., Gruber, R., Riedel, M. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur. Arch. Psychiatry Clin. Neurosci., 2004, 254(1), 14-22. http://dx.doi.org/10.1007/s00406-004-0478-1
41. Müller, N., Riedel, M., Schwarz, M.J., Engel R.R. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci., 2005, 255(2), 149-151. http://dx.doi.org/10.1007/s00406-004-0548-4
42. Akhondzadeh, S., Tabatabaee, M., Amini, H., Ahmadi Abhari, S.A., Abbasi, S.H., Behnam, B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr. Res., 2007, 90(1-3), 179-85. http://dx.doi.org/10.1016/j.schres.2006.11.016
43. Rapaport, M.H., Delrahim, K.K., Bresee, C.J., Maddux, R.E., Ahmadpour, O., Dolnak, D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol. Psychiatry., 2005, 57(12), 1594-1596. http://dx.doi.org/10.1016/j.biopsych.2005.02.024
44. Sommer, I.E., van Westrhenen, R., Begemann, M.J., de Witte, L.D., Leucht, S., Kahn, R.S. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull., 2014, 40(1), 181-191. doi: 10.1093/schbul/sbt139.
45. Keller, W.R., Kum, L.M., Wehring, H.J., Koola, M.M., Buchanan, R.W., Kelly, D.L. A review of anti-inflammatory agents for symptoms of schizophrenia. J. Psychopharmacol., 2013, 27(4), 337-342. doi: 10.1177/0269881112467089.
46. Mansur, R.B., Zugman, A., Asevedo, E.M., da Cunha, G.R., Bressan, R.A., Brietzke, E. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin. Neurosci., 2012, 66(4), 247-260. doi: 10.1111/j.1440-1819.2012.02354.x.
47. Griffin, É.W., Skelly, D.T., Murray, C.L., Cunningham, C. Cyclooxygenase-1-dependent prostaglandins mediate susceptibility to systemic inflammation-induced acute cognitive dysfunction. J. Neurosci., 2013, 33(38), 15248-15258. doi: 10.1523/JNEUROSCI.6361-11.2013.
48. Müller, N., Myint, A.M., Krause, D., Weidinger, E., Schwarz, M.J. Anti-inflammatory treatment in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2013, 42, 146-153. doi: 10.1016/j.pnpbp.2012.11.008
49. Bresee, C.J., Delrahim, K., Maddux, R.E., Dolnak, D., Ahmadpour, O., Rapaport, M.H. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int. J. Neuropsychopharmacol., 2006, 9(3), 343-348. http://dx.doi.org/10.1017/S1461145705005808
50. Martínez-Gras, I., Pérez-Nievas, B.G., García-Bueno, B., Madrigal, J.L., Andrés-Esteban, E., Rodríguez-Jiménez, R., Hoenicka, J., Palomo, T., Rubio, G., Leza, J.C. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr. Res., 2011, 128(1-3), 15-22. doi: 10.1016/j.schres.2011.01.018
51. Faridhosseini, F., Sadeghi, R., Farid, L., Pourgholami, M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum. Psychopharmacol., 2014, 29(3), 216-223. doi: 10.1002/hup.2401.
52. Eyre, H.A., Air, T., Proctor, S., Rositano, S., Baune, B.T. A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2015, 57, 11-16. doi: 10.1016/j.pnpbp.2014.10.003. Epub 2014 Oct 16.
53. Johansson, D., Falk, A., Marcus, M.M., Svensson, T.H. Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 39(1), 143-148. doi: 10.1016/j.pnpbp.2012.06.003.
54. Chen, C.Y., Tzeng, N.S., Chen, Y.C. Maintenance therapy of celecoxib for major depression with mimicking neuropsychological dysfunction. Gen. Hosp. Psychiatry, 2010, 32(6), 647.e7-9. doi:10.1016/j.genhosppsych.2010.07.001.
55. Krause, D.L., Riedel, M., Müller, N., Weidinger, E., Schwarz, M.J., Myint, A.M. Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients. Inflammopharmacology, 2012, 20(3), 169-176. doi: 10.1007/s10787-011-0112-6.
56. Gallagher, P.J., Castro, V., Fava, M., Weilburg, J.B., Murphy, S.N., Gainer, V.S., Churchill, S.E., Kohane, I.S., Iosifescu, D.V., Smoller, J.W., Perlis, R.H. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am. J. Psychiatry, 2012, 169(10), 1065-1072. doi: 10.1176/appi.ajp.2012.11091325.
57. Nery, F.G., Monkul, E.S., Hatch, J.P., Fonseca, M., Zunta-Soares, G.B., Frey, B.N., Bowden, C.L., Soares, J.C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol., 2008, 23(2), 87-94. doi: 10.1002/hup.912
58. Goldstein, B.I., Kemp, D.E., Soczynska, J.K., McIntyre, R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry, 2009, 70(8), 1078-1090. doi: 10.4088/JCP.08r04505.
59. Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science, 2002, 298 (5594), 789-791. http://dx.doi.org/10.1126/science.1074069
60. Hsieh, H.L., Yang, C.M. Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed. Res. Int., 2013, 484613. doi: 10.1155/2013/484613.
61. Hoozemans, J., Rozemuller, J.M., van Haastert, E.S., Veerhuis, R., Eikelenboom, P. Cyclooxygenase-1 and-2 in the different stages of Alzheimer's disease pathology. Curr. Pharm. Des., 2008, 14(14), 1419-1427. http://dx.doi.org/10.2174/138161208784480171
62. Aïd, S., Bosetti, F. Targeting cyclooxygenases-1 and-2 in neuroinflammation: Therapeutic implications. Biochimie, 2011, 93(1), 46-51. doi: 10.1016/j.biochi.2010.09.009.
63. Melnikova, T., Savonenko, A., Wang, Q., Liang, X., Hand, T., Wu, L., Kaufmann, W.E., Vehmas, A., Andreasson, K.I. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience, 2006, 141(3), 1149-1146. http://dx.doi.org/10.1016/j.neuroscience.2006.05.001
64. Cakała, M., Malik, A.R., Strosznajder, J.B. Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. Pharmacol. Rep., 2007, 59(2), 164-172.
65. Kumari, B., Kumar, A., Dhir, A. Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stressinduced behavioral and biochemical alterations. Pharmacol. Rep., 2007, 59(6), 699-707
66. Soininen, H., West, C., Robbins, J., Niculescu, L.: Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2007, 23(1), 8-21. http://dx.doi.org/10.1159/000096588
67. Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers. Dement., 2013, 9(6), 714-723. doi: 10.1016/j.jalz.2012.11.012.
68. Reines, S.A., Block, G.A., Morris, J.C., Liu, G., Nessly, M.L., Lines, C.R., Norman, B.A., Baranak, C.C. Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology, 2004, 62(1), 66-71. http://dx.doi.org/10.1212/WNL.62.1.66
69. Thal, L.J., Ferris, S.H., Kirby, L., Block, G.A., Lines, C.R., Yuen, E., Assaid, C., Nessly, M.L., Norman, B.A., Baranak, C.C., Reines, S.A. Rofecoxib Protocol 078 study group. A randomized, doubleblind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology, 2005, 30(6), 1204-1215. http://dx.doi.org/10.1038/sj.npp.1300690
70. Choi, S.H., Aid, S., Caracciolo, L., Minami, S.S., Niikura, T., Matsuoka, Y., Turner, R.S., Mattson, M.P., Bosetti, F. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J. Neurochem., 2013, 124(1), 59-68. doi: 10.1111/jnc.12059.
71. Choi, S.H., Aid, S., Caracciolo, L., Minami, S.S., Niikura, T., Matsuoka, Y., Turner, R.S., Mattson, M.P., Bosetti, F. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J. Neurochem., 2013, 124(1), 59-68. doi: 10.1111/jnc.12059.
72. Wang, H., Hitron, I.M., Iadecola, C., Pickel, V.M. Synaptic and vascular associations of neurons containing cyclooxygenase-2 and nitric oxide synthase in rat somatosensory cortex. Cereb. Cortex, 2005, 15(8), 1250-1260. http://dx.doi.org/10.1093/cercor/bhi008
73. Garcia-Bueno, B., Serrats, J., Sawchenko, P.E.: Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamicpituitary-adrenal axis activation by inflammatory stimuli. J. Neurosci., 2009, 29(41), 12970-12981. doi: 10.1523/JNEUROSCI.2373-09.2009.
74. Liu, X.H., Kirschenbaum, A., Weinstein, B.M., Zaidi, M., Yao, S., Levine, A.C. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells. Biochem. Biophys. Res. Commun., 2010, 394(3), 715-720. doi: 10.1016/j.bbrc.2010.03.057.
75. Ciani, L., Salinas, P.C. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat. Rev. Neurosci., 2005, 6(5), 351-362. http://dx.doi.org/10.1038/nrn1665
76. Wong, C.T., Ahmad, E., Li, H., Crawford, D.A. Prostaglandin E2 alters Wnt-dependent migration and proliferation in neuroectodermal stem cells: implications for autism spectrum disorders. Cell Commun. Signal., 2014, 12:19. doi: 10.1186/1478-811X-12-19.
77. Mostafa, G.A., El-Hadidi, E.S., Hewedi, D.H., Abdou, M.M. Oxidative stress in Egyptian children with autism: relation to autoimmunity. J. Neuroimmunol., 2010, 219(1-2), 114-118. doi: 10.1016/j.jneuroim.2009.12.003.
78. El-Ansary, A., Al-Ayadhi, L. Lipid mediators in plasma of autism spectrum disorders. Lipids Health Dis., 2012, 11:160. doi: 10.1186/1476-511X-11-160.
79. Yorbik, O., Sayal, A., Akay, C., Akbiyi, D.I., Sohmen, T. Investigation of antioxidant enzymes in children with autistic disorder. Prostagland. Leukot. Essent. Fatty Acids, 2002, 67, 341-343. http://dx.doi.org/10.1054/plef.2002.0439
80. Söğüt, S., Zoroğlu, S.S., Ozyurt, H., Yilmaz, H.R., Ozuğurlu, F., Sivasli, E., Yetkin, O., Yanik, M., Tutkun, H., Savaş, H.A., Tarakcioğlu, M., Akyol, O. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiolgical mechanisms involved in autism. Clin. Chim. Acta, 2003, 331(1-2), 111-117. http://dx.doi.org/10.1016/S0009-8981(03)00119-0
81. Zoroglu, S.S., Armutcu, F., Ozen, S., Gurel, A., Sivasli, E., Yetkin, O., Meram, I.: Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur. Arch. Psychiatry Clin. Neurosci., 2004, 254(3), 143-147. http://dx.doi.org/10.1007/s00406-004-0456-7
82. Meguid, N., Dardir, A.A., Abdel-Raouf, E.R., Hashish, A. Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol. Trace Elem. Res., 2011, 143(1), 58-65. http://dx.doi.org/10.1007/s12011-010-8840-9
83. Parellada, M., Moreno, C., Mac-Dowell, K., Leza, J.C., Giraldez, M., Bailón, C., Castro, C., Miranda-Azpiazu, P., Fraguas, D., Arango, C. Plasma antioxidant capacity is reduced in Asperger syndrome. J. Psychiat. Res., 2012, 46(3), 394-401. http://dx.doi.org/10.1016/j.jpsychires.2011.10.004
84. Chauhan, A., Chauhan, V., Brown, W.T., Cohen, I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins. Life Sci., 2004, 75(21), 2539-2549. http://dx.doi.org/10.1016/j.lfs.2004.04.038
85. Tórsdóttir, G., Hreidarsson, S., Kristinsson, J., Snaedal, J., Jóhannesson, T.: Ceruloplasmin, superoxide dismutase and copper in autistic patients. Basic Clin. Pharmacol. Toxicol., 2005, 96(2), 146-148. http://dx.doi.org/10.1111/j.1742-7843.2005.pto960210.x
86. Sakuma, S., Fujimoto, Y., Miyata, Y., Ohno, M., Nishida, H., Fujita, T. Effects of Fe(2+), Zn(2+), Cu(2+) and Se(4+) on the synthesis and catabolism of prostaglandins in rabbit gastric antral mucosa. Prostaglandins Leukot. Essent. Fatty Acids, 1996, 54(3), 193-197. http://dx.doi.org/10.1016/S0952-3278(96)90016-2
87. Ritter, A., Goulitquer, S., Salaün, J.P., Tonon, T., Correa, J.A, Potin, P. Copper stress induces biosynthesis of octadecanoid and eicosanoid oxygenated derivatives in the brown algal kelp Laminaria digitata. New Phytol., 2008, 180, 809-821. http://dx.doi.org/10.1111/j.1469-8137.2008.02626.x
88. Leblanc, C.P., Surette, M.E., Fiset, S., Turgeon O'Brien, H., Rioux, F.M. Maternal iron deficiency and its effect on essential fatty acid and eicosanoid metabolism and spatial memory in the guinea pig offspring. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 81, (1), 1-8. doi: 10.1016/j.plefa.2009.05.023.
89. Farooqui, A.A. Lipid mediators in the neural cell nucleus: their metabolism, signaling, and association with neurological disorders. Neuroscientist, 2009, 15, 392-407. http://dx.doi.org/10.1177/1073858409337035
90. Lee, K.H., Yun, S.J., Nam, K.N., Gho, Y.S., Lee, E.H. Activation of microglial cells by ceruloplasmin. Brain Res., 2007, 1171:1-8. http://dx.doi.org/10.1016/j.brainres.2007.07.053
91. DiSilvestro, R.A., Selsby, J., Siefker, K.: A pilot study of copper supplementation effects on plasma F2alpha isoprostanes and urinary collagen crosslinks in young adult women. J. Trace Elem. Med. Biol, 2010, 24(3), 165-168. doi: 10.1016/j.jtemb.2010.02.003.
92. Fukai, T., Ushio-Fukai, M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid. Redox Signal., 2009, 15, 1583-1606. http://dx.doi.org/10.1089/ars.2011.3999
93. Vu H.V., Lee, S., Acosta, T.J., Yoshioka, S., Abe, H., Okuda, K. Roles of prostaglandin F2alpha and hydrogen peroxide in the regulation of Copper/Zinc superoxide dismutase in bovine corpus luteum and luteal endothelial cells. Reprod. Biol. Endocrinol., 2012, 10:87. Erratum in: Reprod. Biol. Endocrinol., 2013, 11, 82. doi: 10.1186/1477-7827-10-87.
94. Kasibhatla, S., Jessen, K.A., Maliartchouk, S., Wang, J.Y., English, N.M., Drewe, J., Qiu, L., Archer, S.P., Ponce, A.E., Sirisoma, N., Jiang, S., Zhang, H.Z., Gehlsen, K.R., Cai, S.X., Green, D.R., Tseng, B.: A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 12095-12100. http://dx.doi.org/10.1073/pnas.0406731102
95. Erikson, K.M., Pinero, D.J., Connor, J.R., Beard, J.L. Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats. J. Nutr., 1997, 127(10), 2030-2038.
96. Hong, Y., Yang, J., Shen, X., Zhu, H., Sun, X., Wen, X., Bian, J., Hu, H., Yuan, L., Tao, J., Lei, P., Shen, G. Sinomenine hydrochloride enhancement of the inhibitory effects of antitransferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells. Cancer Immunol. Immunother., 2013, 62(3), 447-454. doi: 10.1007/s00262-012-1337-y.
97. Pandey, M.K., Sung, B., Ahn, K.S., Kunnumakkara, A.B., Chaturvedi, M.M., Aggarwal, B.B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood, 2007, 110(10), 3517-3525. http://dx.doi.org/10.1182/blood-2007-03-079616
98. Yui, K., Koshiba, M., Nakamura, S., Kobayashi, Y. Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. J. Clin. Psychopharmacol., 2012, 32(2), 200-206. doi: 10.1097/JCP.0b013e3182485791.
99. Ahmed, M., Neville, M.J., Edelmann, M.J., Kessler, B.M., Karpe, F. Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity, 2009, 18(1), 27-34. http://dx.doi.org/10.1038/oby.2009.208